Literature DB >> 14523532

[Tolerance and effectiveness of oxymetazoline and xylometazoline in treatment of acute rhinitis].

M Dorn1, W Hofmann, E Knick.   

Abstract

BACKGROUND: Local alpha-sympathomimetics in hydrous solution are well known in the therapy of acute rhinitis and sinusitis. However, added preservatives like benzalkonium chloride have a negative effect on compatibility. PATIENTS AND
METHOD: A total of 307 patients with acute rhinitis entered the study. The treatment with oxymetazoline with preservative, oxymetazoline without preservative and xylometazoline with preservative was evaluated.
RESULTS: This randomised, double-blind, multi-centered, verum-controlled tolerance study confirmed that the local sympathomimetics oxymetazoline and xylometazoline are well tolerated in the treatment of acute rhinitis. When evaluated according to the parameters "feeling of dryness in nasal mucosa" and "burning sensation", the Nasivin sanft 0.05% spray, which contains the active agent oxymetazoline without preservatives, proved to be considerably superior to preparations containing the preservative benzalkonium chloride.
CONCLUSION: Preparations without preservatives should be the preferred choice of treatment for acute rhinitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523532     DOI: 10.1007/s00106-003-0869-z

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  15 in total

1.  The effect of different preparations of nasal decongestants on ciliary beat frequency in vitro.

Authors:  T Deitmer; R Scheffler
Journal:  Rhinology       Date:  1993-12       Impact factor: 3.681

2.  Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity.

Authors:  P Graf
Journal:  Rhinology       Date:  1996-03       Impact factor: 3.681

3.  [Effect of topical corticosteroids and topical antihistaminics on ciliary epithelium of human nasal mucosa in vitro].

Authors:  T Hofmann; G Wolf; B Koidl
Journal:  HNO       Date:  1998-02       Impact factor: 1.284

4.  The effect of some preservatives used in nasal preparations on mucociliary clearance.

Authors:  A H Batts; C Marriott; G P Martin; S W Bond
Journal:  J Pharm Pharmacol       Date:  1989-03       Impact factor: 3.765

5.  Oxymetazoline spray in otorhinolaryngology.

Authors:  H L Haines
Journal:  Curr Ther Res Clin Exp       Date:  1966-03

6.  Evaluation of a new oxymetazoline preparation in the treatment of nasal congestion. A multicentre trial.

Authors: 
Journal:  Practitioner       Date:  1975-05

Review 7.  Rhinitis medicamentosa: aspects of pathophysiology and treatment.

Authors:  P Graf
Journal:  Allergy       Date:  1997       Impact factor: 13.146

8.  [Laser Doppler flow signal frequency analysis in physiological and drug modified nasal flow motion].

Authors:  R Siegert; L Klitzing
Journal:  HNO       Date:  1996-09       Impact factor: 1.284

9.  Benzalkonium chloride in a decongestant nasal spray aggravates rhinitis medicamentosa in healthy volunteers.

Authors:  P Graf; H Hallén; J E Juto
Journal:  Clin Exp Allergy       Date:  1995-05       Impact factor: 5.018

10.  Contact allergy to various components of topical preparations for treatment of external otitis.

Authors:  J E Fräki; K Kalimo; P Tuohimaa; E Aantaa
Journal:  Acta Otolaryngol       Date:  1985 Nov-Dec       Impact factor: 1.494

View more
  3 in total

1.  [New generation antihistamines as monotherapy or in combination. What is the relevance for daily clinical routine for allergic rhinoconjunctivitis].

Authors:  R Mösges; J Köberlein
Journal:  HNO       Date:  2007-06       Impact factor: 1.284

2.  [Ultrastructural changes in human nasal mucosa in rhinitis medicamentosa].

Authors:  S Knipping; H J Holzhausen; A Riederer; M Bloching
Journal:  HNO       Date:  2006-10       Impact factor: 1.284

3.  Dexpanthenol: An Overview of its Contribution to Symptom Relief in Acute Rhinitis Treated with Decongestant Nasal Sprays.

Authors:  Ralph Mösges; Kija Shah-Hosseini; Hans-Peter Hucke; Marie-Josefine Joisten
Journal:  Adv Ther       Date:  2017-07-10       Impact factor: 3.845

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.